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Background: The current study aimed to investigate the release of myocardial high-sensitive Troponin T (hsTnT) in
patients with pulmonary arterial hypertension (PAH) in response to maximal physical exercise.
Methods: In 24 patients with PAH, symptom-limited cardiopulmonary exercise testing was performed. hsTnT was
measured by the novel hsTnT assay with a lower limit of detection of 2 ng/L and a total imprecision of less than
10% at the 99th percentile value. hsTnT was related to NT-proBNP, WHO functional class and right ventricular (RV)
function. Serial measurement was performed before and 30 min, 180 min, and 300 min after exercise. Healthy
volunteers served as a control group.
Results: In 21 PAH patients, hsTnT levels were detectable before exercise with a close correlation between hsTnT
and NT-proBNP. hsTnT was detectable in all PAH patients after exercise and significantly increased from 7.5 ng/L at
baseline to 14.62 ng/L after 300 min, whereas levels of NT-proBNP remained constant with time.
Conclusions: Using the novel hsTnT assay, the current study provides first evidence that hsTnT levels increase in
PAH patients after maximal physical exercise, while levels of other biomarkers remain constant after exercise testing.
This might provide new insights into pathophysiology and individual risk assessment in patients with PAH.
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Pulmonary arterial hypertension (PAH) is a progressive
disease leading to reduced functional status with a poor
prognosis [1]. A high pulmonary vascular resistance and
right ventricular dysfunction impair stroke volume of the
right ventricle leading to impaired functional capacity.
Compared to the National Institutes of Health-supported
1980s registry [2], substantial progress has been achieved
in the treatment of PAH due to improved pharmacother-
apy with drugs targeting different molecular targets since.
Exercise training in PAH patients used to be considered
as potentially hazardous. However, the first clinical trial on
exercise training in patients with PAH reported improved
exercise capacity and quality of life [3]. Several follow-up
studies confirmed that exercise training improved endur-
ance and peripheral muscle function in patients with PAH* Correspondence: mirko.voelkers@med.uni-heidelberg.de
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reproduction in any medium, provided the orand supported the role of exercise training as an adjunct
therapeutic regime [3,4]. Moreover, recent studies with
larger patient populations approved safety and efficacy of
closely monitored exercise training in various forms of
pulmonary hypertension, though Grünig et al. character-
ized it as potentially harmful due to the risk of adverse
events [5]. However, negative results of training have been
reported in an experimental model of PAH, where exercise
training was beneficial in stable PAH, but detrimental in
progressive PAH [6]. Today, recommendations regarding
type, frequency or intensity of exercise training are not
enclosed in the current guidelines of PAH treatment.
Cardiac Troponin T (cTnT) is the preferred biomarker
for detection of myocardial cell injury [7]. Well-known
reasons for increased cTnT levels include irreversible
myocardial necrosis in patients with acute coronary syn-
drome as well as direct or indirect myocardial cell damage
due to non-ischemic injury such as toxins or infections.
High-sensitive Troponin T (hsTnT) assays have been re-
cently introduced and are characterized by increasedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions at the 99th percentile on a reference population with
an imprecision of less than 10% [8]. Moreover, the concen-
trations of cardiac markers such as cTnT are known to in-
crease after prolonged exercise to levels seen after minor
myocardial infarction [9]. Two mechanisms of elevated
cTnT values after prolonged exercise have been postulated
and include either an increase in myocardial injury due to
the true breakdown of myocytes or the cytosolic release of
the biomarker [10,11].
Recently, we showed that elevated concentrations of
hsTnT predict advanced WHO functional class and
death in patients with PAH [12]. Elevated levels of
hsTnT showed a close relation with systolic RV dysfunc-
tion. We designed the study to determine if patients
with PAH in comparision with healthy volunteers de-
velop significant hsTnT release after symptom-limited
cardiopulmonary exercise testing.Methods
This study enrolled 24 patients with PAH. All patients
were treated according to current guidelines for PAH treat-
ment. At time of the exercise testing patient were clinically
stable since at least 4 weeks and none showed clinical signs
of cardiopulmonary decompensation. Patients with severe
renal failure (creatinine clearance <60 mL/min/1.73 m2)
were excluded.
Twelve healthy volunteers served as a control cohort.
Control subjects had no suspicion of any pathological find-
ing in echocardiography at rest, body-plethysmography
and symptom-limited cardiopulmonary exercise testing.
Addtionally, all relevant laboratory values (including
hsTnT, NT-proBNP and creatinin) were within standard
values.Study population
This study was conducted in a university tertiary referral
center for patients with PAH (Department of Cardiology
and Respiratory Medicine, Medical Center, University
Hospital, Heidelberg, Germany) and included patients
with idiopathic PAH (IPAH) and chronic-thrombembolic
pulmonary hypertension (CTEPH) [13]. The diagnosis of
IPAH was made after right heart catheterization, and
ventilation-perfusion scan, spiral computer tomography,
three-dimensional angiography magnetic resonance tom-
ography, or pulmonary angiography to rule out pulmonary
embolic etiology, and after exclusion of underlying auto-
immune disease, collagen vascular disease, hepatic or HIV
infection, and nocturnal deoxygenation. The local ethics
committee approved the study and all patients gave writ-
ten informed consent prior to inclusion. The study was
designed and performed in accordance with the recom-
mendations found in the Helsinki Declaration.Right heart catherterization
Right heart catheter was performed with a Swan-Ganz
catheter from either the right internal jugular or right fem-
oral vein as reported previously [14]. The zero reference
pressure has been estimated in a plane 5 cm dorsally to
the sternal angle. PAPm and PCWPm were measured in
the supine position at rest. Cardiac output (CO) measure-
ments were obtained using the thermodilution method.
CO was calculated as the mean value from 3 measure-
ments with <10% variability of at least 5 measurements.
The measurements were made using the mean at end-
expiration, and were analyzed by two independent investi-
gators from the raw data.
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) was performed
using a progressively increasing work rate to maximum
tolerance on an electromagnetically braked semi-reclining
cycle ergometer (ergoselect 1000, ergoline GmbH, Bitz,
Germany) with an integrated complete cardiorespira-
tory diagnosis system (MasterSreen™ CPX, CareFusion,
Hoechberg, Germany). Heart rate, ECG, ventilation,
carbon dioxide output, oxygen uptake, work rate, end-
tidal carbon dioxide and end-tidal oxygen pressure, as
well as other gas exchange variables were measured
continously as described before [3]. From these data,
the peak oxygen uptake, peak heart rate, peak oxygen
pulse, respiratory exchange ratio (which equals carbon
dioxide output/oxygen uptake), anaerobic threshold,
ventilatory equivalents for oxygen and carbon dioxide
were calculated. The anaerobic threshold was detected
with the V-slope method [15].
Serum biomarkers
Blood samples were drawn from a peripheral vein. Samples
were stored immediately at −80°C. Samples were later ana-
lyzed in batches. hsTnT was measured using the new
hsTnT quantitative electrochemiluminescence immuno-
assay (Roche Diagnostics, Mannheim, Germany) as de-
scribed previously [12]. The assay is specific for Troponin
T without relevant interferences and has an analytic range
of 3–10000 ng/L (limit of the blank/LOB 3 ng/L, limit of
quantification/LOQ 14 ng/L). A concentration of 14 ng/L
has been identified as the 99th percentile of a healthy refer-
ence population with a CV of <10%. Routine laboratory
parameter measurements including NT-proBNP and cre-
atinine were performed at the core laboratory of the
University Hospital of Heidelberg.
Six-minute walk test
The results of the six-minute walk test (6-MWT) were
counted from the laps achieved on a 60-m course in a
straight hospital hallway. The test equipment and the
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commended [14].
Data analysis
Statistical analysis was performed by a professional stat-
istician using standard software (SAS 9.1 WIN). Results
are expressed as mean ± standard deviation (SD). Paired
and unpaired Student's t-test and Pearson's correlation
coefficient were analyzed as appropriate. P-values < 0.05
were considered statistically significant.
Results
The baseline characteristics of the patients are presented
in Table 1. We included 24 patients with PAH. PH was
idiopathic in 15 patients and thromboembolic in 9 pa-
tients. Among these 24 patients, 15 patients (62%) were in
WHO functional class II and 9 patients (38%) in WHO
functional class III. The mean pulmonary arterial pressure
was 48.72 ± 18.69 mmHg. The peak oxygen uptake after
maximal exercise on standardized spiroergometry wasTable 1 Patients’ and control cohort characteristics
n = 24 Mean ± SD




BMI (kg/cm2) 27,17 ± 6.45
SvO2 (%) 62.86 ± 7.92
PAmean (mmHg) 48.72 ± 18.69
PVR (dyn*s*cm-5) 638.18 ± 381.06
Mean RAP (mmHg) 10.82 ± 4.63
Workload max (Watt) 74.61 ± 21.07
Peak VO2 (ml/kg/min) 13.32 ± 3.3
SysRRmax (mmHg) 153.56 ± 32.42
NT-proBNP (ng/L) 363.39 ± 461.68
6-MWT (m) 428.52 ± 118.96
Ejection fraction (%) 55.13 ± 4.34
Diastolic LV-dysfunction (%) 41.67
History of CAD (%) 12.5
Creatinin (mg/dL) 1.12 ± 0.83
Control cohort characteristics
n = 12 mean ± SD
Age (years) 36.8 ± 10.7
Male (%) 58
Workload max (Watt) 244.58 ± 60.56
Peak VO2 (ml/kg/min) 38.73 ± 11.34
NT-proBNP (ng/L) 31.65 ± 42.4913.32 ± 3.3 VO2 mL/kg/min and severely impaired com-
pared to the control cohort. To compare the effect of
symptom-limited physical exercise on hsTnT we included
12 healthy volunteers with no known cardiopulmonary
diseases. The control cohort was younger and achieved a
significantly higher maximal workload ( 244.58 ± 60.56 vs
74.61 ± 21.07 Watt) and Peak VO2 (38.73 ± 11.34 vs 13.32 ±
3.3 mL/kg/min) compared with the PAH patients.
To address the question if symptom-limited exercise in-
creased hsTnT levels in patients with PAH, we took blood
samples at 30 min, 180 min and 300 min after CPET.
Figure 1 illustrates the study design. Twenty out of 24 pa-
tients had detectable hsTnT at baseline before exercise,
compared to only 3 out of 12 healthy volunteers. Whereas
hsTnT levels were <14 ng/L (limit of quantification) in
these control subjects (3.34 ng/L, 3.96 ng/L and 5.97 ng/L),
hsTnT baseline values were >14 ng/L and thus pathologic-
ally elevated in 4 patients. Elevated hsTnT levels are associ-
ated with death and decreased right ventricle function in
patients with PAH [14]. We found a close relationship
between hsTnT levels and NT-proBNP at baseline (r = 0.7,
p < 0.01) as well as 5 hours after maximal exercise (r = 0.667,
p < 0.01) (Figure 2A and 2B).
Interestingly, concentration of hsTnT increased in
PAH patients after exercise with time and reached sig-
nificance 5 hours post CPET (Figure 3A and 3C). Serum
concentrations of NT-proBNP remained constant after
exercise (Figure 3B and 3D). Conversely, no detectable
increase in hsTnT serum concentrations was observed in
the control cohort. As well, the control cohort had no
change in serum concentration of NT-proBNP (Figure 3E
and 3F).
Next, we correlated the individual increase of hsTnT
serum concentrations (ΔhsTnT) in each individual
PAH patient with the mean pulmonary arterial pres-
sure (Figure 4A) and with serum levels of NT-proBNP
(Figure 4B). Interestingly, the severity of the PAH
(measured by mean mPAP) correlated with the ΔhsTnT
and with the NT-proBNP plasma levels, whereas ΔhsTnT
failed to correlated with the maximal workload (Figure 4B)
or peak oxygen uptake (data not shown).
Discussion
To our best knowledge, this is the first study to investi-
gate hsTnT release in PAH patients after cardiopulmo-
nary exercise testing. The major finding of the present
study is that symptom-limited exercise using standard-
ized cardiopulmonary exercise testing in PAH patients
leads to significantly increased serum level of hsTnT.
We demonstrated a time dependent increase of serum
levels of hsTnT, which was not detectable in a healthy
control cohort.
The role of physical exercise in current clinical man-









Figure 1 Schematic flow chart of the study design. Blood was taken before the exercise and 30 min, 180 min and 300 min after exercise
testing.
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tients were advised to limit their physical activity. Exer-
cise was thought to increase the workload for the
already compromised right ventricle. Recently, a pro-
spective study by Merelez et al. [3] showed that exercise
training remarkably improved exercice capacity and
quality of life in clinically stable patients. In accordance,
another study demonstrated exercise training improved
endurance and muscle function [1]. However, it remains
uncertain if over-ambicious exercise training with re-
peated symptom-limited physical activity can contribute
to myocardial damage in PAH patients. Interestingly, a
recent study showed that exercise training was detri-
mental in mice with progressive PAH, resulting in ad-
verse effects on hemodynamics and accelerated the
progression of right heart failure [4].
It is well known that RV systolic dysfunction transi-
ently occurs after prolonged physical exercise i.e. mara-
thon running in endurance athletes. It has been shown
in several studies that cardiac biomarkers are elevated
after strenuous exercise such as marathon [9,16-18]. The
transient RV systolic dysfunction was linked to exercise
induced pulmonary hypertension [19]. Therefore it is
tempting to speculate that in PAH patients the elevated
pulmonary arterial pressure is causal for the elevated
hsTnT after exercise. This is also supported by the fact
that healthy volunteers showed no increase in hsTnTA


























Figure 2 HsTnT correlates with NT-proBNP concentrations in patients
testing (B).after symptom-limited brief exercise. However, it cannot
be excluded from the data raised in this study, whether
comorbid left ventricular systolic or diastolic dysfunction
or coronary artery disease may have contributed to
hsTnT elevation in some PAH patients.
Controversies exist regarding the mode of Troponin T
release, i.e. membrane leakage vs. cardiomyocytes necrosis.
The first hypothesis is supported by the finding of short
and quantitatively small Troponin release in patients with
significant pulmonary embolism [11,20]. Other findings
support the hypothesis that Troponin release is caused by
cardiomyocyte necrosis. Immunhistochemical studies have
demonstrated that cardiac Troponin is only released after
irreversible cardiomyocyte damage [10]. However, low
serum concentrations of Troponin T are detectable in
healthy subjects with the new hsTnT quantitative elec-
trochemiluminescence immunoassay [21], as observed in
our control cohort. Although values <14 ng/L are not con-
sidered as pathological, the mechanism of Troponin T re-
lease in those subjects is currently not known. In
summary the underlying pathological mechanisms for the
increase in hsTnT in our patients remains to be elucidated
by further studies.
It should be noted that the majority of our patients
belonged to the WHO FC II and was clinically stable at
the time of the examination in order to tolerate the exer-
cise test. We were able to detect hsTnT in 83% of ourB


























































































































































Figure 3 Plasma levels of hsTnT increased time-dependently after exercise (Scatter Blot A and individual patients C), whereas levels of
NT-proBNP remained constant (Scatter Blot B and individual patients D) in patients with PAH. HsTnT (E) and NT-proBNP (F) remained
unchanged in the healthy control cohort after exercise.
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concentrations of hsTnT after exercise and the relative
increase of hsTnT correlated positively with both mPAP
and serum levels of NT-proBNP. Therefore we speculate
that the release of hsTnT after exercise is dependent on
RV function and increased right ventricular wall stress
in patients with more severe PAH. This finding could be
of clinical relevance as maximal exercise in patients with
severe PAH and progressive right ventricular failure
could cause a clinically significant increase in hsTnT.
However, there are some limitations in regard to
interpreting the study results. 21 of the 24 PAH patientsanalysed had hsTnT levels that were above the lower
level of detection (LOB 3 pg/mL) but below the level of
quantification (LOQ 14 pg/mL) before exercise. Due to
measurement uncertainty, hsTnT levels at this level remain
to be of clinically questionable relevance. Nevertheless, 12
patients with initial hsTnT > 3 pg/mL < 14 pg/mL con-
verted to serum concentrations > 14 pg/mL after CPET.
Moreover, there was a uniform tendency towards elevated
hsTnT values after exercise in all PAH patients which oc-
curred irrespective of the initial hsTnT level.
Yet, some major issues remain to be elucidated. Due
to the small sample size and the stable clinical
(r=0.4, p<0.05)




















































Figure 4 Correlation between ΔhsTnT and clinical parameters. Correlation between ΔhsTnT and mPAP (A) and NT-proBNP (B) showed
positive correlation whereas ΔhsTnT and maximal Workload (C) showed no correlation.
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address the question whether increased Troponin release
after exercise predicts fatal events or clinical worsening.
Future follow up studies will address these questions.
Moreover, hsTnT was serially measured after symptom-
limited and very short exercise. This does not reflect
controlled exercise and respiratory training used in pre-
vious clinical studies. If controlled exercise-training can
cause relevant hsTnT release in patients with progressive
RV dysfunction remains to be investigated. However,
many patients with severe PAH want to exercise more
than they are allowed to and we expect that further re-
search is required to optimize training programs for
PAH patients at early and late stages.Conclusions
The current study demonstrates for the first time that
serum levels of hsTnT increased after symptom-limited
exercise testing in patients with PAH. Our study sup-
ports the role of increased right ventricular wall stress in
the release of cardiac Troponin in PAH. Exercise testing
with assessment of hsTnT might provide new insightsinto pathophysiology and individual risk assessment in
patients with PAH.
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